fezakinumab 
GtoPdb Ligand ID: 9281
|
Synonyms: ILV-094
Compound class:
Antibody
Comment: Fezakinumab is a fully human monoclonal anti-IL22 antibody being investigated for clinical antiinflammatory utility against acute and chronic conditions.
Peptide sequence and structural information for this antibody are available from its IMGT/mAb-db record. Peptide sequences identical to those of the heavy and light variable regions of fezakinumab are claimed in patent US7811567, leading to identification of clone 356A11 as fezakinumab [1]. |
| Immunopharmacology Disease | |||
| Disease | X-Refs | Comment | References |
| Psoriasis |
Disease Ontology:
DOID:8893 |
Completed Phase 1 trial for psoriasis (see NCT00563524). | |
| Atopic dermatitis |
Disease Ontology:
DOID:3310 OMIM: 603165 |
Active Phase 2 study NCT01941537. | |
| Rheumatoid arthritis |
Disease Ontology:
DOID:7148 OMIM: 180300 |
Completed Phase 2 trial for RA (see NCT00883896). | |
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License